Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sigvotatug vedotin + pembrolizumab + cisplatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen of **sigvotatug vedotin** (an investigational antibody-drug conjugate targeting nectin-4), **pembrolizumab** (a monoclonal antibody that inhibits PD-1, marketed as Keytruda), and **cisplatin** (a platinum-based chemotherapy). This combination is being investigated for the treatment of various advanced solid cancers, leveraging distinct and complementary mechanisms: sigvotatug vedotin delivers cytotoxic agents directly to tumor cells expressing nectin-4, pembrolizumab enhances immune-mediated tumor cell killing by releasing PD-1-mediated inhibition of T cells, and cisplatin induces tumor cell DNA damage leading to apoptosis, and also has immunomodulatory effects. No unique brand name for the combination.
- Brand names
- none for sigvotatug vedotin (investigational)none for cisplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNAITGB6 (Integrin beta-4)
Beyond the preview
Go deeper on sigvotatug vedotin + pembrolizumab + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sigvotatug vedotin + pembrolizumab + cisplatin.